Product Highlight - Dapagliflozin (Forxiga)
28 Feb 2024
Dapagliflozin (Forxiga) is indicated in adults with Type 2 Diabetes Mellitus for:
- The treatment of diabetes as an adjunct to diet and exercise.1
- The prevention of new or worsening heart failure or cardiovascular death.1
- The prevention of new or worsening nephropathy.1
Dapagliflozin (Forxiga) is indicated in adults for the treatment of chronic kidney disease.1
Dapagliflozin (Forxiga) is indicated in adults for the treatment of heart failure.1
In the Dapa CKD study, Dapagliflozin (Forxiga) reduced the risk of eGFR decline, ESKD, or renal or CV death by 39%, significantly reduced the risk of all-cause mortality by 31%, and CV death or hHF by 29% in patients with CKD, with and without T2D.2
In the pooled analysis of the Dapa HF and DELIVER studies, Dapagliflozin (Forxiga) reduced hospitalization for heart failure by 29% in as early as 13 days and CV death by 14%, across the range of LVEF.3
REFERENCES:
1. Dapagliflozin (Forxiga™) Full Prescribing Information. AstraZeneca Pharmaceuticals Phils. Inc. March 2023.
2. Heerspink HJL, et al. N Engl J Med 2020;383:1436–1446.
3. Jhund PS et al. Nat Med. 2022;28(9):1956-1964
AstraZeneca Pharmaceuticals (Phils.), Inc.
16/F Inoza Tower 40th St.,
Bonifacio Global City, Taguig City 1634
Tel No: AZ Med Info: (+63-2) 8777 8804
